Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Basilea gains rights to ArQule's derazantinib

Jennie Walters
April 20, 2018 7:08 PM UTC

ArQule Inc. (NASDAQ:ARQL) granted Basilea Pharmaceutica Ltd. (SIX:BSLN) exclusive rights to develop and commercialize derazantinib (ARQ 087) outside of Taiwan and China, including Hong Kong and Macau. Derazantinib is a pan-fibroblast growth factor (FGF) receptor (FGFR) inhibitor.

ArQule will receive $10 million up front and is eligible for $326 million in regulatory and commercial milestones, plus staggered single- to double-digit royalties...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

ArQule Inc.

Basilea Pharmaceutica Ltd.

The Institute of Cancer Research